Best AI drug discovery platforms

Nearly every published answer to this question is an ordered list, and an ordered list requires a weighting: a decision about which failure matters most. That decision belongs to the research organization carrying the program, not to whoever wrote the list. Publishing an order does not remove the weighting. It hides it inside a position number that looks like a measurement.

Two buyers can correctly reach opposite conclusions about the same vendor. A large pharmaceutical company with its own medicinal chemistry team may want licensed software it can run behind its own firewall and will accept thinner evidence to get it. A small biotech with one target and no computational group may want a partner that takes the target all the way to a candidate, and will care about outcomes far more than about where the software runs. There is no order that is right for both.

So what follows is the whole roster graded on the same axes, then shortlists cut by failure mode. It is a longer read than a top ten, and it is the only version of this page that would survive being checked.

The first question is not which vendor is best. It is what kind of relationship you are buying, because this category contains at least three, and they are not interchangeable.

Some vendors sell software your own scientists license and run. Some sell a discovery collaboration, where you bring a target and they bring molecules under a negotiated agreement, with no product to install. And some are building their own pipelines and partner selectively, so what they offer you is access to a program rather than to a platform.

The difference decides which axes matter. Deployment and data residency are real questions for licensed software and barely apply to a collaboration, where the answer lives in the contract. Commercial terms are published for a few software products and almost never for collaborations. Read a vendor’s grades with its engagement model in mind, and the grid stops looking contradictory.

Of the 40 vendors graded here, 36 are primarily drug discovery companies. At the date on this page the other 4 are pathology AI companies that sell image analysis into pharmaceutical research, for biomarker discovery and for preclinical and trial pathology. They belong on this page because a research buyer evaluating them is evaluating a discovery capability.

Every vendor in the index carries a grade on all 15 axes before it is published at all, so this table compares the same questions answered for every vendor rather than the results of uneven research. Counts are of vendors, as of September 25, 2026.

Several axes were written for clinical buyers and read here as their research equivalents. Record system depth becomes integration with research informatics such as electronic lab notebooks and laboratory information systems. AI Governance and Bias Disclosure becomes chemical and biological representativeness, and for open design models, dual use release governance. Most records grade the patient data axes as not applicable, because the platforms run on structures and assay data, so this page draws no conclusion from those two rows.

Read the top of the table and the category looks like what it is: a field that grew out of computational science and publishes like one. 33 vendors hold a top grade on AI Centrality, which here means the model is the product rather than a layer on a wet lab. 14 hold a top grade on Model and Technology Transparency, more than on any other axis in this category apart from centrality.

A lower centrality grade describes the mechanism, not the quality. A platform built on physics simulation that uses machine learning as a layer is graded for exactly that, and the best of them say so openly.

This is the finding this page was worth building for. 14 of 40 vendors hold a top grade on Model and Technology Transparency. 0 hold a top grade on Security Certifications and Trust Center, and 10 sit at the bottom grade.

Consider what a buyer hands over. A pharmaceutical partner in a discovery collaboration specifies targets it has not disclosed publicly, which is among the most valuable information it owns. Some collaborations go further and send the partner’s own experimental data to the vendor. The whole engagement depends on that material entering an environment the partner does not control.

None of this means the security is poor. Large pharmaceutical partners run their own vendor security reviews, and a vendor with several of them has almost certainly passed one privately. What is missing is publication. A smaller buyer, without that review capacity, has nothing to read.

The practical answer is architectural where it can be. 3 vendors in this category hold a top grade on Deployment Model and Data Residency, which means software that can run inside the buyer’s own environment, so the chemistry never leaves. Everywhere else, the question moves into the contract. Ask what the vendor holds in its own name as distinct from what its cloud provider holds, whether partner data sits in a separated environment, and what the vendor’s own staff can see.

This is the question no single axis captures, and it is the one most worth asking in this category. Several platforms improve their models on the experimental data their partners generate. That is often the point of the collaboration, and it can be a good deal for both sides.

The risk is what happens to what the model learned. A model improved on your assay data is then used for the next partner, who may be your competitor, and nothing in most published material says where that learning is bounded. A few vendors answer it directly, by training separate models for each customer and stating that the customer owns what it designs on the platform. Most say nothing either way.

Four questions settle it, and they belong in the first substantive conversation rather than in the final contract. Does our data train a model other partners use? Are our targets and results separated from other partners at rest and in training? What happens to models trained on our data when the collaboration ends? And who owns the molecules the platform proposes for our targets?

7 of 40 vendors hold a top grade on Clinical and Operational Evidence and none sits at the bottom grade. That is a better evidence posture than most categories in this index, and the shape of the evidence still needs reading carefully.

Three things get presented as evidence in this field and are not. A deal value is a statement about what a partner believes, not a demonstration that the platform works. A long list of named collaborations shows traction, and the index does not treat scale of use as evidence of benefit. And a clinical stage pipeline can be acquired or licensed in, which says nothing about the discovery engine that is being sold.

What does count is harder to fake. A partner confirming a predicted target in its own lab, at its own cost. A prospective study that reports its failures alongside its hits. A molecule designed on the platform moving through clinical trials.

The strongest position is evidence plus a published method. 4 of 40 vendors hold a top grade on both, which means an outside scientist can examine how the result was produced as well as the result itself. The list is in the shortlists below.

A note on FDA and Regulatory Status. Discovery platforms are not medical devices, and regulatory standing belongs to the molecule and to whoever owns it. So the axis records whether a vendor states that position correctly and how far platform derived candidates have progressed. 3 vendors hold a top grade on it and none sits at the bottom.

AI Liability and Recourse returns a top grade for nobody at all in this category, and 15 of 40 sit at the bottom grade. Across all 545 vendors this index grades, in every category, exactly 1 earns an A on that axis, so this is an industry position rather than a category one.

The shape of the harm is different here. There is no patient at the point of use. The party that bears a bad prediction is the partner’s research program, which can spend years and a great deal of capital on a wrong direction.

That makes the collaboration agreement the whole of the accountability story. Ask what it says about performance representations, and what evidence of model behavior you are entitled to inspect when a designed asset fails. A closed model with vendor generated benchmarks leaves nothing to measure a shortfall against.

Each list below is every vendor in the category holding the top grade on the named axes. They are not ranked, they are alphabetical, and a vendor appearing on none of them is not disqualified. It has not published what these axes ask for, which is a question to raise rather than a verdict.

An empty list is a result rather than a gap in the research. It says the question currently has no vendor level answer available in public, which makes it a question for the first meeting instead of a filter.

If more than one of these is your failure mode, take the intersection yourself rather than looking for a vendor that appears everywhere. Almost none do, which is the point of the next section.

The widest record in the category holds a top grade on 5 axes of 15. The median record holds 2. There is no vendor here that clears every bar, and a comparison built on the assumption that one exists will end in a tie broken by brand recognition.

Breadth of modality is its own axis and it varies widely. 7 vendors hold a top grade on Setting and Specialty Coverage, which here means work across several modalities, such as small molecules, antibodies and other proteins, rather than one. A small molecule team cannot use a protein design model and a protein engineering team cannot use a small molecule tool, so check modality before anything else on this page.

The right number of finalists is small and specific. Two or three vendors that clear your one non negotiable axis will produce a better process than ten that all look plausible on a capability grid.

Every AI drug discovery vendor in the index, each graded on all 15 axes with a source and a date on every judgment. Inclusion is not purchasable and no vendor pays for placement or review.